Pharmacotherapy of cognition in schizophrenia

Current Opinion in Behavioral Sciences

Volumn 4, Issue , 2015, Pages 115-121

  Meltzer, Herbert Y ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR; CLOZAPINE; DOPAMINE; GROWTH FACTOR; HALOPERIDOL; LURASIDONE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORCLOZAPINE; OLANZAPINE; PERPHENAZINE; PHENCYCLIDINE; PIMAVANSERIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE; TANDOSPIRONE;

BRAIN CORTEX; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GENETIC HETEROGENEITY; GLUTAMATERGIC SYNAPSE; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; MENTAL PATIENT; META ANALYSIS; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RODENT; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT RESPONSE;

EID: 84935851811     PISSN: None     EISSN: 23521546     Source Type: Journal    
DOI: 10.1016/j.cobeha.2015.04.009     Document Type: Review

References (61)

1. Keefe R.S., Harvey P.D. Cognitive impairment in schizophrenia. Handb Exp Pharmacol 2012, 11-37.
2. Hyman S.E. Time for new schizophrenia Rx. Science 2014, 343:1177.
3. Balu D.T., Coyle J.T. The NMDA receptor 'glycine modulatory site' in schizophrenia: d-serine, glycine, and beyond. Curr Opin Pharmacol 2015, 20C:109-115.
4. Sohal V.S. Identifying pathways leading to prefrontal GABA-ergic interneuron dysfunction in schizophrenia. Am J Psychiatry 2014, 171:906-909.
5. Kimoto S., Bazmi H.H., Lewis D.A. Lower expression of glutamic acid decarboxylase 67 in the prefrontal cortex in schizophrenia: contribution of altered regulation by Zif268. Am J Psychiatry 2014, 171:969-978.
6. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25:1-27.
7. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci U S A 1992, 89:4270-4274.
8. Simpson E.H., Kellendonk C., Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65:585-596.
9. Bruins Slot L.A., Lestienne F., Grevoz-Barret C., Newman-Tancredi A., Cussac D. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur J Pharmacol 2009, 620:27-35.
10. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002, 956:349-357.
11. Rajji T.K., Mulsant B., Davies S., Kalache S., Tsoutsoulas C., Pollock B., Remington G. Clozapine to n-desmethylclozapine plasma concentrations ratio predicts working memory performance in schizophrenia. Am J Psychiatry 2015, (in press).
12. Meltzer H.Y. Attention must be paid: the plasma clozapine/N-desmethylclozapine (NDMC) ratio association with working memory and its relevance to the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). Am J Psychiatry 2015, (in press).
13. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., Wong P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 2008, 105:5585-5590.
14. Cahill M.E., Remmers C., Jones K.A., Xie Z., Sweet R.A., Penzes P. Neuregulin1 signaling promotes dendritic spine growth through kalirin. J Neurochem 2013, 126:625-635.
15. Meltzer H.Y., Rajagopal L., Huang M., Oyamada Y., Kwon S., Horiguchi M. Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2013, 16:2181-2194.
16. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64:633-647.
17. Caroff S.N., Davis V.G., Miller D.D., Davis S.M., Rosenheck R.A., McEvoy J.P., Campbell E.C., Saltz B.L., Riggio S., Chakos M.H., et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 2011, 72:295-303.
18. March J., Kraemer H.C., Trivedi M., Csernansky J., Davis J., Ketter T.A., Glick I.D. What have we learned about trial design from NIMH-funded pragmatic trials?. Neuropsychopharmacology 2010, 35:2491-2501.
19. Waddington J.L., Youssef H.A., Dolphin C., Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 1987, 44:907-912.
20. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J.C., Meltzer H.Y. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2010, 332:622-631.
21. Bedard M.A., Scherer H., Stip E., Cohen H., Rodriguez J.P., Richer F. Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cogn 2000, 43:31-39.
22. Chudasama Y., Robbins T.W. Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol Psychol 2006, 73:19-38.
23. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007, 89:211-224.
24. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993, 34:702-712.
25. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122.
26. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999, 25:201-222.
27. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
28. Desamericq G., Schurhoff F., Meary A., Szoke A., Macquin-Mavier I., Bachoud-Levi A.C., Maison P. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol 2014, 70:127-134.
29. Guilera G PO, Gómez-Benito J., Rojo J.E. Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials. Eur J Psychiatry 2009, 23:77-89.
30. Nielsen R.E., Levander S., Kjaersdam Telleus G., Jensen S.O., Ostergaard Christensen T., Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 2015, 131:185-196.
31. Wagner M., Quednow B.B., Westheide J., Schlaepfer T.E., Maier W., Kuhn K.U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005, 30:381-390.
32. Horiguchi M., Huang M., Meltzer H.Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011, 338:605-614.
33. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994, 55(Suppl. B):82-87.
34. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Rock S.L., Woolson S., Tohen M., Tollefson G.D., et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 2006, 59:97-105.
35. Guo X., Zhai J., Wei Q., Twamley E.W., Jin H., Fang M., Hu M., Zhao J. Early-stage Schizophrenia Outcome Study I: neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 2011, 503:141-146.
36. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Kunz M., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002, 159:1018-1028.
37. Horiguchi M., Hannaway K.E., Adelekun A.E., Huang M., Jayathilake K., Meltzer H.Y. D(1) receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats. Behav Brain Res 2013, 238:36-43.
38. Silva A.J. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. J Neurobiol 2003, 54:224-237.
39. Kurnianingsih Y.A., Kuswanto C.N., McIntyre R.S., Qiu A., Ho B.C., Sim K. Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. J Neural Transm 2011, 118:1621-1639.
40. Luoni A., Rocha F.F., Riva M.A. Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2014, 50:94-101.
41. Corvin A., Donohoe G., Hargreaves A., Gallagher L., Gill M. The cognitive genetics of neuropsychiatric disorders. Curr Top Behav Neurosci 2012, 12:579-613.
42. Stip E., Mancini-Marie A., Letourneau G., Fahim C., Mensour B., Crivello F., Dollfus S. Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study. Int Clin Psychopharmacol 2009, 24:34-41.
43. Meltzer H.Y., Lindenmayer J.P., Kwentus J., Share D.B., Johnson R., Jayathilake K. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res 2014, 154:14-22.
44. Meltzer H.Y., Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008, 172:177-197.
45. Woolley M.L., Waters K.A., Reavill C., Bull S., Lacroix L.P., Martyn A.J., Hutcheson D.M., Valerio E., Bate S., Jones D.N., et al. Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat. Behav Pharmacol 2008, 19:765-776.
46. Rowe A.R., Mercer L., Casetti V., Sendt K.V., Giaroli G., Shergill S.S., Tracy D.K. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J Psychopharmacol 2015, 29:197-211.
47. Bolbecker A.R., Shekhar A. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions. Handb Exp Pharmacol 2012, 167-190.
48. Nikiforuk A. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Rev Neurosci 2014, 25:367-382.
49. Gasbarri A., Pompili A. Serotonergic 5-HT7 receptors and cognition. Rev Neurosci 2014, 25:311-323.
50. Goto Y., Yang C.R., Otani S. Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biol Psychiatry 2010, 67:199-207.
51. Couey J.J., Meredith R.M., Spijker S., Poorthuis R.B., Smit A.B., Brussaard A.B., Mansvelder H.D. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron 2007, 54:73-87.
52. Aoyama Y., Mouri A., Toriumi K., Koseki T., Narusawa S., Ikawa N., Mamiya T., Nagai T., Yamada K., Nabeshima T. Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. Int J Neuropsychopharmacol 2014, 17:723-737.
53. Hagihara H., Takao K., Walton N.M., Matsumoto M., Miyakawa T. Immature dentate gyrus: an endophenotype of neuropsychiatric disorders. Neural Plast 2013, 2013:318596.
54. Ferguson G.D., Vician L., Herschman H.R. Synaptotagmin IV: biochemistry, genetics, behavior, and possible links to human psychiatric disease. Mol Neurobiol 2001, 23:173-185.
55. Beesley P.W., Herrera-Molina R., Smalla K.H., Seidenbecher C. The Neuroplastin adhesion molecules: key regulators of neuronal plasticity and synaptic function. J Neurochem 2014, 131:268-283.
56. Lisman J.E., Otmakhova N.A. Storage, recall, and novelty detection of sequences by the hippocampus: elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine. Hippocampus 2001, 11:551-568.
57. Wang X.J. Neurophysiological and computational principles of cortical rhythms in cognition. Physiol Rev 2010, 90:1195-1268.
58. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., Siegel S.J. Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull 2010, 83:147-161.
59. Young J.W., Amitai N., Geyer M.A. Behavioral animal models to assess pro-cognitive treatments for schizophrenia. Handb Exp Pharmacol 2012, 39-79.
60. Meltzer H.Y., Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behav Brain Res 2008, 195:98-102.
61. Oyamada Y., Horiguchi M., Rajagopal L., Miyauchi M., Meltzer H.Y. Combined serotonin (5-HT) agonism, 5-HT and dopamine D receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Behav Brain Res 2014.